Great post, thanks.
I have not been happy with the company's poor communication over the last year, as I feel we investors have often paid the price being hyped up by ENZC for good things that don't happen, and left completely in the dark when bad things do happen. But the number of issues ENZC was sorting out behind the scenes is impressive when summarized together as you did. Each appointment and subsidiary and debt negotiation and share class restructuring slowly brought us to where we are today, which is a decidedly better place than where ENZC was a couple years ago.
It's easy to see how all this baggage would have gotten in the company's way had they tried to sweep it all under the rug and spent 100% of their energy on bringing products to market. Obviously that's incredibly important too -- but not if the skeletons could rise up and sink them before they even really got started.
They've also been working with CDMOs and universities and biolabs and marketing firms, sometimes in multiple countries, amidst drama like pulled PRs and broken centrifuges. Patent offices, audit teams and now OTC lawyers. Four different lawsuits. Youtube interviews and the retail convention. Possible investors and future partners we haven't met yet. All that stuff takes time and energy too.
Now hoping enough ducks are in a row they can shift focus to growth goals, and we start seeing some bigger news drop soonishly. :)
News 
Market Data 
Discover 
